Show simple item record

dc.contributor.authorSalamero, O.
dc.contributor.authorMontesinos, P.
dc.contributor.authorWillekens, C.
dc.contributor.authorPérez-Simón, J. A.
dc.contributor.authorPigneux, A.
dc.contributor.authorRécher, C.
dc.contributor.authorPopat, R.
dc.contributor.authorCarpio, C.
dc.contributor.authorMolinero, C.
dc.contributor.authorMascaró, C.
dc.contributor.authorVila, J.
dc.contributor.authorArévalo, M. I.
dc.contributor.authorMaes, T.
dc.contributor.authorBuesa, C.
dc.contributor.authorBosch, F.
dc.contributor.authorSomervaille, Tim C P
dc.date.accessioned2020-11-16T07:49:15Z
dc.date.available2020-11-16T07:49:15Z
dc.date.issued2020en
dc.identifier.citationSalamero O, Montesinos P, Willekens C, Perez-Simon JA, Pigneux A, Recher C, et al. First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol. 2020:JCO1903250.en
dc.identifier.pmid33052756en
dc.identifier.doi10.1200/jco.19.03250en
dc.identifier.urihttp://hdl.handle.net/10541/623429
dc.description.abstractPurpose: Iadademstat is a novel, highly potent, and selective inhibitor of LSD1 (KDM1A), with preclinical in vitro and in vivo antileukemic activity. This study aimed to determine safety and tolerability of iadademstat as monotherapy in patients with relapsed/refractory acute myeloid leukemia (R/R AML). Methods: This phase I, nonrandomized, open-label, dose-escalation (DE), and extension-cohort (EC) trial included patients with R/R AML and evaluated the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antileukemic activity of this orally bioavailable first-in-class lysine-specific demethylase 1 inhibitor. Results: Twenty-seven patients were treated with iadademstat on days 1 to 5 (5-220 µg/m2/d) of each week in 28-day cycles in a DE phase that resulted in a recommended dose of 140 µg/m2/d of iadademstat as a single agent. This dose was chosen to treat all patients (n = 14) in an EC enriched with patients with MLL/KMT2A-rearranged AML. Most adverse events (AEs) were as expected in R/R AML and included myelosuppression and nonhematologic AEs, such as infections, asthenia, mucositis, and diarrhea. PK data demonstrated a dose-dependent increase in plasma exposure, and PD data confirmed a potent time- and exposure-dependent induction of differentiation biomarkers. Reductions in blood and bone marrow blast percentages were observed, together with induction of blast cell differentiation, in particular, in patients with MLL translocations. One complete remission with incomplete count recovery was observed in the DE arm. Conclusion: Iadademstat exhibits a good safety profile together with signs of clinical and biologic activity as a single agent in patients with R/R AML. A phase II trial of iadademstat in combination with azacitidine is ongoing (EudraCT No.: 2018-000482-36).en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/jco.19.03250en
dc.titleFirst-in-human phase I study of iadademstat (ORY-1001): a first-in-class lysine-specific histone demethylase 1a inhibitor, in relapsed or refractory acute myeloid leukemiaen
dc.typeArticleen
dc.contributor.departmentHospital Vall d'Hebron, Vall D'Hebron Institute of Oncology, Departament de Medicina, Universitat Autònoma de Barcelona, UAB, Barcelona, Spain.en
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]
refterms.dateFOA2020-11-16T15:59:40Z


Files in this item

Thumbnail
Name:
33052756.pdf
Size:
1.110Mb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record